The peptide problem: Hype is outrunning the evidence |
Health Canada recently warned Canadians not to buy or inject unauthorized peptide drugs sold online, naming products that include BPC-157, CJC-1295, ipamorelin, TB-500 and retatrutide.
The advisory notes these products are being marketed online and on social media for anti-aging, weight loss, injury recovery, sleep, mental focus and general “wellness,” and that Health Canada has already seized several of them.
Peptides, short chains of amino acids (the building blocks of protein), are no longer marketed only to bodybuilders and elite athletes.
A scroll on Instagram and TikTok quickly reveals a broader wellness market in which influencers, including medical doctors, naturopaths and personal trainers, pitch compounds such as BPC-157 and TB-500. The hook? These self-injected compounds are recovery shortcuts, reduce wrinkles, “melt” belly fat and are “anti-aging” with strong and incredible effects.
The problem? Few, if any, of these substances have been tested in human trials.
As a case example, body protective compound 157 (BPC-157) is scientifically interesting. Reviews published in 2025 describe a body of research dominated by animal and cell studies, with signals suggesting effects on angiogenesis (the growth of blood vessels), growth-factor signalling (mainly growth hormone) and musculoskeletal healing.
In one systematic review, 544 papers were screened, 36 met the inclusion criteria, and 35 of those were in rodents or cells; only one involved humans in a musculoskeletal context.
That is the tension at the heart of the current peptide boom: plausible biology can generate excitement long before it generates reliable clinical evidence. Caution is warranted because animal findings do not reliably map onto what happens in people. Molecular pathway diagrams and rodent healing results are useful for generating scientific hypotheses, but they aren’t evidence that a product........